Tafluprost now licensed worldwide

Article

A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd.

A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd.

The drug belongs to the prostaglandin class and is designed for the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. It already has marketing approval in several European and Nordic countries and is marketed under the trademark of TAFLOTAN in Germany, Denmark, Finland, Sweden and Norway.

Merck has paid an undisclosed sum based on future sales in exchange for commercial rights to tafluprost in Western Europe, with the exception of Germany, North and South America and Africa.

"The licensing of tafluprost from Santen, a company with extensive experience in ophthalmics, further expands Merck's strong portfolio of topical treatments in ophthalmology," said Vlad Hogenhuis, MD, senior vice president and general manager, neuroscience and ophthalmology, Merck. "After 50 years, Merck remains committed to advancing ophthalmic research and expanding global outreach to improve therapeutic options for patients."

Akira Kurokawa, president and CEO of Santen Ltd., described the agreement as: "An important milestone in the development and commercialization of tafluprost, Through this licensing agreement with Merck, we are well positioned to significantly expand our access to additional markets."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.